FDA clears at-home subcutaneous induction for Skyrizi in Crohn’s disease

Federal prosecutors charge 15 in a Los Angeles health care fraud takedown, the FDA approves bepirovirsen (Hibsago) for chronic hepatitis B, and Skyrizi gains at-home subcutaneous induction for Crohn’s disease.